Immunomedics (IMMU) 10-Q 6 May 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2015	5-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	IMMU
Entity Registrant Name	IMMUNOMEDICS INC
Entity Central Index Key	722830
Current Fiscal Year End Date	-24
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		93,464,463

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Jun. 30, 2014
ASSETS
Cash and cash equivalents	$16,063,159	$6,961,494
Marketable securities	90,129,300	34,871,120
Accounts receivable, net of allowance for doubtful accounts of $62,024 at March 31, 2015 and $88,609 at June 30, 2014	598,164	674,617
Inventory	624,367	778,989
Other receivables	185,381	303,102
Prepaid expenses	1,637,025	1,614,897
Other current assets	378,513	180,678
Total current assets	109,615,909	45,384,897
Property and equipment, net of accumulated depreciation of $27,721,469 and $27,312,924 at March 31, 2015 and June 30, 2014, respectively	2,065,311	1,895,475
Other long-term assets	152,405	206,110
Total Assets	111,833,625	47,486,482
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses	8,824,995	6,886,682
Deferred revenues	230,759	240,158
Total current liabilities	9,055,754	7,126,840
Convertible senior notes - net of unamortized debt issuance costs of $3,557,878 at March 31, 2015	96,442,122
Other liabilities	1,574,881	1,500,244
Commitments and Contingencies
Stockholders' Equity:
Preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at March 31, 2015 and June 30, 2014
Common stock, $0.01 par value; authorized 155,000,000 shares at March 31, 2015 (135,000,000 at June 30, 2014); issued 93,479,501 shares and outstanding 93,444,776 shares at March 31, 2015; and issued 93,113,480 shares and outstanding 93,078,755 shares at June 30, 2014	934,794	931,134
Capital contributed in excess of par	302,180,742	300,080,804
Treasury stock, at cost, 34,725 shares at March 31, 2015 and at June 30, 2014	-458,370	-458,370
Accumulated deficit	-297,067,440	-261,465,638
Accumulated other comprehensive (loss) income	-243,729	261,837
Total Immunomedics, Inc. stockholders' equity	5,345,997	39,349,767
Noncontrolling interest in subsidiary	-585,129	-490,369
Total stockholders' equity	4,760,868	38,859,398
Total Liabilities and Stockholders' Equity	$111,833,625	$47,486,482

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$62,024	$88,609
Property and equipment, accumulated depreciation	27,721,469	27,312,924
Unamortized debt issuance costs	$3,557,878
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	155,000,000	135,000,000
Common stock, shares issued	93,479,501	93,113,480
Common stock, shares outstanding	93,444,776	93,078,755
Treasury stock, shares	34,725	34,725

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product sales	$694,329	$925,235	$2,183,626	$2,434,159
License fee and other revenues	250,000		250,000	4,623,333
Research and development	238,369	229,106	823,861	797,120
Total revenues	1,182,698	1,154,341	3,257,487	7,854,612
Costs and Expenses:
Costs of goods sold	72,771	90,253	218,040	270,523
Costs of license fee and other revenues				1,189,170
Research and development	10,385,422	8,141,744	30,142,289	23,221,651
Sales and marketing	285,708	243,692	689,140	886,234
General and administrative	1,564,536	2,200,526	7,239,764	5,975,278
Total costs and expenses	12,308,437	10,676,215	38,289,233	31,542,856
Operating loss	-11,125,739	-9,521,874	-35,031,746	-23,688,244
Interest expense	-720,795		-720,795
Interest and other income, net	32,838	15,179	69,126	39,695
Foreign currency transaction gain (loss)	28,873	-25,894	29,035	-7,902
Loss before income tax expense	-11,784,823	-9,532,589	-35,654,380	-23,656,451
Income tax expense	-3,327	-1,372	-42,182	-1,372
Net loss	-11,788,150	-9,533,961	-35,696,562	-23,657,823
Net loss attributable to noncontrolling interest	-32,003	-28,359	-94,760	-78,778
Net loss attributable to Immunomedics, Inc. stockholders	-11,756,147	-9,505,602	-35,601,802	-23,579,045
Loss per common share attributable to Immunomedics, Inc. stockholders:
Basic and diluted	($0.13)	($0.11)	($0.38)	($0.28)
Weighted average shares used to calculate loss per common share:
Basic and diluted	93,351,708	83,340,329	93,201,307	83,127,073
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	-253,502	3,355	-511,335	123,236
Unrealized gain (loss) on available-for-sale securities	16,220	-4,138	5,769	10,884
Other comprehensive (loss) income	-237,282	-783	-505,566	134,120
Net comprehensive loss	-12,025,432	-9,534,744	-36,202,128	-23,523,703
Net comprehensive loss from noncontrolling interest	-32,003	-28,359	-94,760	-78,778
Net comprehensive loss attributable to Immunomedics, Inc. stockholders	($11,993,429)	($9,506,385)	($36,107,368)	($23,444,925)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($35,696,562)	($23,657,823)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	408,643	424,084
Amortization of debt issuance costs	99,337
Gain on sale of marketable securities	-10,203	-4,193
(Decrease) increase in allowance for doubtful accounts	-20,752	12,037
Non-cash expense related to stock compensation	2,117,582	2,403,293
Amortization of deferred revenue	-9,399	-2,532,016
Non-cash decrease in value of life insurance policy	53,705	32,822
Amortization of deferred rent	74,637	74,637
Amortization of bond premiums	307,227	155,280
Changes in operating assets and liabilities	2,296,242	1,650,434
Net cash used in operating activities	-30,379,543	-21,441,445
Cash flows from investing activities:
Purchases of marketable securities	-82,298,796	-20,097,204
Proceeds from sales of marketable securities	26,748,771	4,015,460
Purchases of property and equipment	-581,528	-317,571
Net cash used in investing activities	-56,131,553	-16,399,315
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes	100,000,000
Payment of debt issuance costs	-3,657,214
Tax withholding payments for stock compensation	-518,995	-286,786
Exercise of stock options	505,011	1,663,346
Net cash provided by financing activities	96,328,802	1,376,560
Effect of changes in exchange rates on cash and cash equivalents	-716,041	127,839
Net increase (decrease) in cash and cash equivalents	9,101,665	-36,336,361
Cash and cash equivalents, beginning of period	6,961,494	41,326,000
Cash and cash equivalents, end of period	$16,063,159	$4,989,639

Business_Overview_and_Basis_of

Business Overview and Basis of Presentation	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Business Overview and Basis of Presentation	1	Business Overview and Basis of Presentation
	Immunomedics is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has continued to transition its focus away from the development and commercialization of diagnostic imaging products in order to accelerate the development of its therapeutic product candidates, although the Company still manufactures and commercializes its LeukoScan® product in territories where regulatory approvals have previously been granted in Europe, Canada and in other markets outside the U.S. LeukoScan® is indicated for diagnostic imaging for determining the location and extent of infection and inflammation in bone of patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The Company has two foreign subsidiaries, Immunomedics B.V. in the Netherlands and Immunomedics GmbH in Darmstadt, Germany, that assist the Company in managing sales efforts and coordinating clinical trials in Europe. In addition, included in the accompanying condensed financial statements is the majority-owned U.S. subsidiary, IBC Pharmaceuticals, Inc. (“IBC”), which works on the development of novel cancer radiotherapeutics using patented pre-targeting technologies with proprietary, bispecific antibodies.
	The accompanying unaudited condensed consolidated financial statements of Immunomedics, which incorporate our subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Regulation S-X. Accordingly, the statements do not include all of the information and footnotes required by GAAP for complete annual financial statements. With respect to the financial information for the interim periods included in this Quarterly Report on Form 10-Q, which is unaudited, management believes that all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the results for such interim periods have been included. Operating results for the three and nine-month periods ended March 31, 2015 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2015, or any other period.
	Immunomedics is subject to significant risks and uncertainties, including, without limitation, the risk that the Company may be unable to successfully obtain financing for product development; the Company’s inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market its drug candidates; the Company’s dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under the Company’s collaborative agreements, if any; uncertainties about the Company’s ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development or regulatory approval of competing products; the Company’s ability to protect its proprietary technologies; patent-infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally.
	As of March 31, 2015, the Company had cash, cash equivalents and marketable securities totaling $106.2 million. In February, 2015 the Company issued $100 million of 4.75% Convertible Senior Notes due 2020 (the “Convertible Notes”) in the aggregate. After deducting the initial purchasers’ fees and offering expenses, the Company received net proceeds of $96.3 million, (see note 4 to the condensed consolidated financial statements).
	Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities and revenues from licensing agreements, which could provide up-front and milestone payments, as well as funding of development costs and other licensing possibilities.
	The Company’s budgeted cash requirements in fiscal year 2015 includes expenses related to the clivatuzumab tetraxetan Phase 3 clinical trial for the treatment of patients with pancreatic cancer, as well as for expenses for the ongoing Phase 2 expansion ADC clinical trials (sacituzumab govitecan and labetuzumab govitecan). For the nine-month period ended March 31, 2015 the Company utilized cash aggregating $30.4 million related to its operating activities. Based on the Company’s cash flow projections, it believes it has sufficient funds to continue its operations and research and development programs for at least the next twelve months.
	Future financial demands include ongoing operating expenses, Phase 3 clinical trials, the Phase 2 clinical trials and further development of various clinical trial programs in fiscal 2016 and 2017. The Company will continue to require additional funding in order to fund its operations and programs.
	The Company continues to pursue business development and licensing arrangements as a potential source of financing. These activities include potential payments from current partners, UCB S.A. (“UCB”) and The Bayer Group (“Bayer”), as well as any new parties who may be interested in the Company’s clinical programs as well as any licenses to the Company’s intellectual property estate. State and Federal Grants, along with potential debt and equity financing may also be other sources of financing.
	Until the Company can generate significant cash from its operations, the Company expects to continue to fund its operations with its available financial resources. These financial resources may not be adequate to sustain its operations and the Company will be required to finance future cash needs through strategic collaboration agreements, or the sale of additional equity or debt securities. However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its stockholders. The capital markets have experienced volatility in recent years, which has resulted in uncertainties with respect to availability of capital and hence the timing to meet an entity’s liquidity needs. Having insufficient funds may require the Company to delay, scale-back or eliminate some or all of its programs or renegotiate less favorable terms than it would otherwise choose. Failure to obtain adequate financing also may adversely affect its ability to operate as a going concern. Additionally, if the Company raises funds by issuing equity securities, dilution to existing stockholders would result; and, if the Company raises additional funds by incurring debt financing, the terms of the debt may involve future cash payment obligations and/or conversion to equity as well as restrictions that may limit its ability to operate its business.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2	Summary of Significant Accounting Policies
	These unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014. The Company adheres to the same accounting policies in preparation of its interim financial statements.
	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
	Marketable Securities
	Marketable securities, all of which are available-for-sale, consists of corporate debt securities, U.S. bonds and U.S. sponsored agencies and municipal bonds. Corporate debt securities include Eurodollar issues of U.S. corporations, and U.S. dollar denominated issues of foreign corporations. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive (loss) income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).
	Inventory
	Inventory, which consists only of the finished product of LeukoScan®, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition,” at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with their clinical sites.
	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
	Stock-Based Compensation
	At the Annual Stockholder Meeting on December 3, 2014, the Company’s stockholders approved the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan replaced the Company’s 2006 Stock Incentive Plan (the “2006 Plan”), which terminated on December 3, 2014. The approval authorized the sum of 9,000,000 shares plus the number of unallocated shares available for issuance as of the effective date under the 2006 Plan that were not subject to outstanding awards.
	The Plan enables the grant of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards. The Plan is described more fully in Note 7 to these condensed consolidated financial statements.
	The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes-Merton option pricing formula for determining the grant-date fair value of such awards.
	The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk free interest rate is based upon the implied yields currently available from the U.S. Treasury yield curve in effect at the time of the grant. Pre-vesting forfeiture rates are estimated based upon past voluntary termination behavior and past option forfeitures.
	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the nine-month periods ended March 31, 2015 and 2014:
			Nine-Month Period Ended March 31,
			2015	2014
	Expected dividend yield		0%	0%
	Expected option term (years)		5.07	3.47
	Expected stock price volatility		59%	66%
	Risk-free interest rate		1.60%-1.67%	0.03%-1.79%
	Changes in any of these assumptions could impact, potentially materially, the amount of expense recorded in future periods related to stock-based awards.
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of March 31, 2015.
	At June 30, 2014, the Company has available net operating loss carry forwards for federal income tax reporting purposes of approximately $173.4 million and for state income tax reporting purposes of approximately $66.2 million, which expire at various dates between fiscal 2015 and 2034. Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, the annual utilization of a company’s net operating loss and research credit carry forwards may be limited if the Company experiences a change in ownership of more than 50 percentage points within a three-year period.
	The majority-owned subsidiary of the Company (IBC Pharmaceuticals, Inc.) is currently under examination by the Internal Revenue Service for the fiscal year ended December 31, 2013.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three and nine-month periods ended March 31, 2015 and 2014. The Company’s U.S. operations reported a net loss for the three and nine-month periods ended March 31, 2015 and 2014, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of March 31, 2015.
	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three and nine-month periods ended March 31, 2015 and 2014. The common stock equivalents excluded from the diluted per share calculation are 26,759,915 and 7,388,212 shares at March 31, 2015 and 2014, respectively.
	Net Comprehensive Loss
	Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
	Reclassification
	Certain prior period balances have been reclassified to conform to the current period presentation.
	Accounting Pronouncements
	In April 2015, the FASB issued Accounting Standard Update (“ASU”) 2015-03, “Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. Under the new ASU, debt issuance costs will be reported in the balance sheet as a direct deduction from the related debt liability rather than as a separate asset. Amortization of the costs is reported as interest expense. The amendments in this update are effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted for financial statements that have not been previously issued. The Company has adopted this standard in the current interim period and have presented the debt issuance costs related to the Convertible Notes as a direct deduction from the related face value in the accompanying condensed consolidated balance sheet.
	In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements – Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This guidance clarifies that an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The amendments in this update are effective for annual reporting periods ending after December 15, 2016, and annual and interim periods thereafter, and early application is permitted. The Company is assessing ASU 2014-15’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-12’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. On April 1, 2015, the FASB voted to propose to defer the effective date on the new revenue recognition standard by one year. Therefore, public organizations would apply the new standard to annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.

Marketable_Securities

Marketable Securities	9 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3	Marketable Securities
	Immunomedics adopted Accounting Standards Codification No. 320, Accounting for Investments—Debt and Equity Securities, to account for investments in marketable securities. Under this accounting standard, securities for which there are no positive intent and ability to hold to maturity, the securities are classified as available-for-sale and are carried at fair value. Unrealized holding gains and losses, which are deemed to be temporary, on securities classified as available-for-sale are carried as a separate component of accumulated other comprehensive (loss) income. Immunomedics considers all of its current investments to be available-for-sale.
	Marketable securities at March 31, 2015 consist of the following (in thousands):
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		(Loss)
	March 31, 2015
	U.S. Treasury Bonds		$	13,690	$	12	$	—		$	13,702
	U.S. Government Sponsored Agencies			46,383		21		(9	)		46,395
	Corporate Debt Securities			30,051		5		(24	)		30,032
			$	90,124	$	38	$	(33	)	$	90,129
	Maturities of debt securities classified as available-for-sale were as follows at March 31, 2015 (in thousands):
			Fair Value		Net Carrying
					Amount
	Due within one year		$	38,344	$	38,442
	Due after one year through five years			51,785		52,064
			$	90,129	$	90,506
	Marketable securities at June 30, 2014 consist of the following (in thousands):
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds		$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies			7,458		—		(1	)		7,457
	Corporate Debt Securities			18,876		12		(11	)		18,877
			$	34,871	$	13	$	(13	)	$	34,871
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
			Fair Value		Net Carrying
					Amount
	Due within one year		$	25,336	$	25,449
	Due after one year through five years			9,535		9,603
			$	34,871	$	35,052

Convertible_Senior_Notes

Convertible Senior Notes	9 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Senior Notes	4	Convertible Senior Notes
	In February 2015, the Company issued $100.0 million of Convertible Notes (net proceeds of $96.3 million after deducting the initial purchasers’ fees and offering expenses) in a private offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon Rule 144A under the Securities Act. The Convertible Notes will mature on February 15, 2020, unless earlier purchased or converted. The debt issuance costs of approximately $3.7 million, primarily consisting of underwriting, legal and other professional fees, will be amortized over the term of the Convertible Notes. The Convertible Notes were senior unsecured obligations of the Company. Interest at 4.75% will be payable semiannually on February 15 and August 15 of each year, beginning on August 15, 2015. The effective interest rate on the Convertible Note was 5.48% for the period from the date of issuance through March 31, 2015.
	The Convertible Notes are convertible at the option of holders into approximately 19.6 million shares of Immunomedics common stock at any time prior to the close of business on the day immediately preceding the maturity date. The conversion rate will initially be 195.8336 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $5.11 per share of Immunomedics common stock).
	If the Company undergoes a fundamental change (as defined in the indenture governing the Convertible Notes), holders may require Immunomedics to purchase for cash all or part of the Convertible Notes at a purchase price equal to 100% of the principal amount of the Convertible Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date, subject to certain exceptions. In addition, if certain make-whole fundamental changes (as defined in the indenture governing the Convertible Notes) occur, Immunomedics will, in certain circumstances, increase the conversion rate for any Convertible Note converted in connection with such make-whole fundamental change.
	The indenture does not limit the amount of debt which may be issued by the Company under the indenture or otherwise, does not contain any financial covenants or restrict the Company from paying dividends or issuing or repurchasing its other securities. The indenture contains customary terms and covenants and events of default.
	If an event of default with respect to the Convertible Notes occurs, holders may, upon satisfaction of certain conditions, accelerate the principal amount of the Convertible Notes plus premium, if any, and accrued and unpaid interest, if any. In addition, the principal amount of the Convertible Notes plus premium, if any, and accrued and unpaid interest, if any, will automatically become due and payable in the case of certain types of bankruptcy or insolvency events of default involving the Company.
	Total interest expense for the Convertible Notes was $0.7 million for the three and nine-month period ended March 31, 2015 including amortization of debt issuance costs of $0.1 million.

Estimated_Fair_Value_of_Financ

Estimated Fair Value of Financial Instruments	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Estimated Fair Value of Financial Instruments	5	Estimated Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses, and Convertible Notes. The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments as of March 31, 2015 and June 30, 2014.
	The Company has categorized its other financial instruments, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Cash, cash equivalents and marketable securities:
	Financial assets recorded on the condensed consolidated balance sheets as of March 31, 2015 and June 30, 2014 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	March 31, 2015		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	11,859	$	—	$	—	$	11,859
	Marketable Securities:
	U.S. Treasury Bonds			13,702		—		—		13,702
	U.S. Government Sponsored Agencies			46,395		—		—		46,395
	Corporate Debt Securities			30,032		—		—		30,032
	Total		$	101,988	$	—	$	—	$	101,988
			($ in thousands)
	June 30, 2014		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	367	$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537		—		—		8,537
	U.S. Government Sponsored Agencies			7,457		—		—		7,457
	Corporate Debt Securities			18,877		—		—		18,877
	Total		$	35,238	$	—	$	—	$	35,238
	The money market funds noted above are included in cash and cash equivalents.
	Convertible Notes
	The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the Convertible Notes as of March 31, 2015 was $99.6 million.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	6	Stockholders’ Equity
	At the Annual Stockholder Meeting on December 3, 2014, the Company’s stockholders approved the amendment and restatement of the Company’s Certificate of Incorporation to increase the maximum number of shares of the Company’s stock authorized up to 165,000,000 shares of stock consisting of 155,000,000 shares of common stock and 10,000,000 shares of preferred stock. Previously the Company’s Certificate of Incorporation authorized up to 145,000,000 shares of stock consisting of 135,000,000 shares of common stock and 10,000,000 shares of preferred stock.
	On October 1, 2014, the Company’s registration statement on Form S-3, as filed with the U.S. Securities and Exchange Commission, (the “SEC”) on September 16, 2014, was deemed effective, using a “shelf” registration process. Under this shelf registration statement, the Company may issue, in one or more offerings, any combination of common stock, preferred stock senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $130.0 million.
	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized			Accumulated Other
			Translation			(Losses) Gains  on			Comprehensive
			Adjustments			Available-for-Sale			Income
						Securities
	Balance, July 1, 2014		$	261,924		$	(87	)	$	261,837
	Other comprehensive (loss) income before reclassifications			(511,335	)		15,972			(495,363	)
	Amounts reclassified from accumulated other comprehensive income (loss)(a)			—			(10,203	)		(10,203	)
	Net current-period other comprehensive (loss) income			(511,335	)		5,769			(505,566	)
	Balance, March 31, 2015		$	(249,411	)	$	5,682		$	(243,729	)
	Balance, July 1, 2013		$	161,830		$	—		$	161,830
	Other comprehensive income before reclassifications			123,236			15,077			138,313
	Amounts reclassified from accumulated other comprehensive income(a)			—			(4,193	)		(4,193	)
	Net current-period other comprehensive income			123,236			10,884			134,120
	Balance, March 31, 2014		$	285,066		$	10,884		$	295,950
	(a)	For the nine-months ended March 31, 2015 and 2014, $10,203 and $4,193 was reclassified from accumulated other comprehensive income to interest and other income, respectively.
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.

Stock_Incentive_Plan

Stock Incentive Plan	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Incentive Plan	7	Stock Incentive Plan
	At the Annual Stockholder Meeting on December 3, 2014, the Company’s stockholders approved the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan replaced the Company’s 2006 Stock Incentive Plan (the “2006 Plan”), which terminated on December 3, 2014. The Plan was established to promote the interests of the Company, by providing eligible persons with the opportunity to acquire a proprietary interest in the Company as an incentive to remain with the organization and to align the employee’s interest with our stockholders. The approval authorized issuance of 9,000,000 shares plus the number of unallocated share available for issuance as of the effective date under the 2006 Plan that were not subject to outstanding awards.
	As under the 2006 Plan, option awards under the Plan are generally granted with an exercise price equal to the market price of the Plan, the Company’s common stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Option awards that are granted to non-employee Board members under the annual option grant program are granted with an exercise price equal to the market price of the Company’s common stock at the date of grant, are vested immediately and have seven year contractual terms. At March 31, 2015, there were 18,434,788 shares of common stock reserved for possible future issuance under the Plan, both currently outstanding (6,176,555 shares) and which were available to be issued for future grants (12,258,233 shares).
	The weighted average fair value at the date of grant for options granted during the nine-month periods ended March 31, 2015 and 2014 were $1.61 and $1.94 per share, respectively. The Company uses historical data to estimate employee forfeitures for employees, executive officers and outside directors. The expected term of options granted represents the period of time that options granted are expected to be outstanding and the expected stock price volatility is based on the Company’s daily stock trading history. The weighted average of the expected option term increased to 5.07 years for the nine-month period ended March 31, 2015 from 3.47 years for the nine-month period ended March 31, 2014 as a result of the issuance of short-term options to the former chief financial officer in the prior year. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The lower risk-free interest rate results from the short-term rate for the stock options granted to the former chief financial officer for the nine-month period ended March 31, 2014.
	Information concerning options for the nine-month period ended March 31, 2015 is summarized as follows:
			Shares			Weighted		Weighted		Aggregate
						Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Life
	Outstanding, July 1, 2014			5,308,617		$	3.41
	Granted			694,923		$	3.57
	Exercised			(178,625	)	$	3.03
	Cancelled or forfeited			(399,750	)	$	4.54
	Outstanding, March 31, 2015			5,425,165		$	3.34		3.24	$	3,817,459
	Exercisable, March 31, 2015			4,105,123		$	3.18		2.42	$	3,441,461
	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2014, and changes during the nine-month period ended March 31, 2015 are presented below:
	Outstanding Non-Vested		Number
	Restricted and Performance Stock Units		of Awards
	Non-vested at July 1, 2014			788,364
	Restricted Units Granted			277,313
	Vested			—
	Exercised			(314,287	)
	Non-vested at March 31, 2015			751,390
	The Company has 2,071,432 non-vested options, restricted and performance stock units outstanding as of March 31, 2015. As of March 31, 2015, there was $3.1 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is being recognized over a weighted-average period of 2.6 years. The Company recorded $0.6 million and $2.1 million for total stock-based compensation expense for employees, executive officers and non-employee Board members for the three and nine-month periods ended March 31, 2015, respectively, as compared to $0.9 million and $2.4 million for the three and nine-month periods ended March 31, 2014, respectively.
	Each non-employee Board member who continues to serve shall receive on the date of the annual stockholders meeting an annual grant of non-qualified stock options and restricted stock units, each equal in value to $45 thousand. The Company recorded $44 thousand and $135 thousand for stock-based compensation expense for these non-employee Board members restricted stock units for the three and nine-month periods ended March 31, 2015, respectively, as compared to $44 thousand and $159 thousand for the three and nine-month periods ended March 31, 2014, respectively.
	On August 14, 2014, the Company awarded an additional 226,657 restricted stock units to certain executive officers of the Company at the market price on that date ($3.32 per share). These restricted stock units will vest over a four-year period. As of March 31, 2015, there was $1.4 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan for these executive officers, excluding performance stock units. The cost is being recognized over a weighted-average period of 2.5 years. The Company recorded $0.2 million and $0.6 million for stock-based compensation expense for these executive officers for the three and nine-month periods ended March 31, 2015, as compared to $0.2 million and $0.5 million for the three and nine-month periods ended March 31, 2014, respectively.
	On August 16, 2013, the Company also awarded certain executive officers Performance Units of up to 389,864 units of restricted stock units which are subject to attainment of certain performance milestones as well as certain continued service requirements. All or a portion of the Performance Units vest based upon the level of achievement of the milestones set forth in each agreement, which is expected to be achieved within five years of the grant date. The Performance Units that vest based upon attainment of the Performance Milestone will be exercised based on a percentage basis on the attainment of anniversary dates. As of March 31, 2015, 116,959 of the total Performance Units were vested based on the achievement of certain performance milestones, which are currently outstanding. The remaining 272,905 Performance Units are available if the remaining performances are achieved within five years of grant date. The Company recorded $0.1 million and $0.3 for the stock-based compensation for the three and nine-month periods ended March 31, 2015, as compared to $0.5 million and $1.3 million for the stock-based compensation for the three and nine-month periods ended March 31, 2014, respectively. There is $0.5 million of total unrecognized compensation cost related to these non-vested Performance Units granted as of March 31, 2015. That cost is being recognized over a weighted-average period of 2.2 years. The unrecognized compensation cost is subject to modification on a quarterly basis based on review of performance probability and requisite achievement periods.

Geographic_Segments

Geographic Segments	9 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Geographic Segments	8	Geographic Segments
	Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan® throughout Europe and in certain other countries outside the United States.
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three and nine-months ended March 31, 2015 and 2014 ($ in thousands):
			As of and for the
			three-months ended
			March 31, 2015
			United			Europe			Total
			States
	Total assets		$	110,600		$	1,234		$	111,834
	Property and equipment, net			2,056			9			2,065
	Revenues			489			694			1,183
	(Loss) before taxes			(11,762	)		(23	)		(11,785	)
			As of and for the
			three-months ended
			March 31, 2014
			United			Europe			Total
			States
	Total assets		$	24,074		$	2,179		$	26,253
	Property and equipment, net			1,980			—			1,980
	Revenues			242			912			1,154
	(Loss) income before taxes			(9,586	)		53			(9,533	)
			Nine-months ended
			March 31, 2015
			United			Europe			Total
			States
	Revenues		$	1,110		$	2,147		$	3,257
	(Loss) income before taxes			(35,733	)		79			(35,654	)
			Nine-months ended
			March 31, 2014
			United			Europe			Total
			States
	Revenues		$	5,453		$	2,402		$	7,855
	(Loss) before taxes			(23,588	)		(68	)		(23,656	)

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	9	Related Party Transactions
	Certain of the Company’s affiliates, including members of its senior management and its Board of Directors, as well as their respective family members and other affiliates, have relationships and agreements among themselves as well as with the Company and its affiliates, that create the potential for both real, as well as perceived, conflicts of interest. These include Dr. David M. Goldenberg, the Chairman of the Board of Directors and Chief Scientific Officer, Ms. Cynthia L. Sullivan, the President and Chief Executive Officer, who is the wife of Dr. David M. Goldenberg, and certain companies with which the Company does business, including the Center for Molecular Medicine and Immunology (“CMMI”), and the Company’s majority-owned subsidiary IBC.
	The Company incurred legal expenses on behalf of CMMI for patent related matters for the three and nine-month period ended March 31, 2015 of $8 thousand and $30 thousand, respectively, as compared to $10 thousand and $23 thousand for the three and nine-month periods ended March 31, 2014, respectively. The Company has first rights to license those patents and may decide whether or not to support them. However, any inventions made independently of the Company at CMMI are the property of CMMI. On occasion, CMMI engages in research contracts on behalf of Immunomedics, Inc. However, for the three and nine-month periods ended March 31, 2015 and 2014 there were no research related activities charged to the Company
	For the three-month and nine-month periods ended March 31, 2015, Dr. Goldenberg received approximately $21 thousand and $63 thousand, respectively, and approximately $20 thousand and $59 thousand for the three-month and nine-month periods ended March 31, 2014, respectively, in compensation for his services to IBC.

License_and_Collaboration_Agre

License and Collaboration Agreements	9 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
License and Collaboration Agreements	10	License and Collaboration Agreements
	Takeda Pharmaceutical/Nycomed GmbH
	On July 11, 2008, the Company entered into the Nycomed Agreement (the “Agreement”) with Nycomed providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company’s humanized anti-CD20 antibody, in the subcutaneous formulation, for the treatment of all non-cancer indications. The Company retained the rights to develop, manufacture and commercialize veltuzumab in the field of oncology. On September 30, 2011, Takeda Pharmaceutical Company Limited (“Takeda-Nycomed”) completed its acquisition of Nycomed and made Nycomed a wholly owned subsidiary.
	Takeda-Nycomed was solely responsible for the development, manufacturing, regulatory approval and commercialization of veltuzumab and the development, manufacturing and regulatory approval of the subcutaneous formulation for all non-cancer indications. The Company’s major obligations were to complete the research and development activities as specified in the Nycomed Agreement and to manufacture and supply veltuzumab to Takeda-Nycomed for the quantity of materials for the period of time specified in the Nycomed Agreement. The Company completed all of its obligations under the agreement, namely its manufacturing and supply obligations and its responsibilities in the Phase 1/2 study in immune thrombocytopenic purpura (“ITP”).
	On October 3, 2013, Takeda-Nycomed delivered notice of termination of the Nycomed Agreement subsequent to the Company’s filing of arbitration proceedings concerning delays in Takeda-Nycomed’s development of veltuzumab, which the Company argued was a material breach of the Agreement. In response to the Company’s claim for damages for the delays, Takeda-Nycomed made certain counterclaims against the Company. The Company responded by filing its own Statement of Defense on November 12, 2013, denying Takeda and Takeda-Nycomed’s allegations and contesting Takeda or Takeda-Nycomed’s rights to any relief. An arbitrator was appointed later that month.
	On December 16, 2014, the Company was notified that the arbitrator awarded no money to either party and the award was in full settlement of all claims and counterclaims submitted to arbitration. All rights to veltuzumab have reverted back to the Company as a result of the termination.
	UCB, S.A.
	On May 9, 2006, the Company entered into an agreement with UCB, S.A. referred to herein as UCB, providing UCB an exclusive worldwide license to develop, manufacture, market and sell epratuzumab for the treatment of all non-cancer indications referred to herein as the UCB Agreement. Under the terms of the UCB Agreement, the Company received from UCB a non-refundable cash payment totaling $38.0 million. On December 27, 2011, the Company entered into the Amendment Agreement with UCB referred to herein as the Amendment Agreement. The Amendment Agreement provided UCB the right to sublicense epratuzumab, subject to obtaining the Company’s prior consent, to a third party for the United States and certain other territories. As of March 31, 2015, UCB has not executed a sublicense agreement with a third-party.
	The Company also issued to UCB on December 27, 2011 a 5-year warrant to purchase one million shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $8.00 per share. In exchange for the right to sublicense its rights in epratuzumab to a third party and the warrant issuance, the Company received a non-refundable cash payment of $30.0 million in January 2012. Further, under the terms of the Amendment Agreement, UCB surrendered its buy-in right with respect to epratuzumab in the field of oncology, which had been granted under the UCB Agreement.
	Collectively, pursuant to the UCB Agreement and the Amendment Agreement the Company is entitled to receive (i) up to $145.0 million in cash payments and $20.0 million in equity investments in regulatory milestone payments and (ii) up to $260.0 million related to the achievement of specified product sales milestones. The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement and Amendment Agreement during the product royalty term, (subject to reduction in certain circumstances). No development milestone, commercialization milestone or royalty payments were achieved through March 31, 2015. There can be no assurance that the development or commercialization milestones or royalty payment thresholds under the UCB Agreement and Amendment Agreement will be met and therefore there can be no assurance that the Company will receive such future payments.
	The Agreement commenced on May 9, 2006 and shall terminate in accordance with the terms thereof or by mutual written consent, unless UCB decides to cease all development and commercialization of epratuzumab pursuant to the Agreement. Either the Company or UCB has the right to terminate the Agreement by notice in writing to the other party upon or after any material breach of the Agreement by the other party, if the other party has not cured the breach within 60 days after written notice to cure has been given, with certain exceptions. Upon termination of the Agreement, among other things, all rights and licenses granted by the Company to UCB shall terminate, all rights of UCB under the Immunomedics Patent Rights, as defined in the Agreement and Immunomedics Know-How (as defined in the Agreement) shall revert to the Company, and UCB shall cease all use of the Immunomedics Patent Rights and Immunomedics Know-How. Further, all regulatory filings and Approvals (as defined in the Agreement) and any other documents relating to or necessary to further develop and commercialize the Licensed Compound (as defined in the Agreement) and Licensed Products (as defined in the Agreement), including, without limitation, all sublicenses granted by UCB, and all of UCB’s right, title and interest therein and thereto, shall be assigned to the Company at the Company’s option. No additional amounts shall be payable on events occurring after the effective date of termination.
	The Bayer Group (formerly Algeta ASA)
	In January 2013, the Company entered into a collaboration agreement, referred to herein as the Collaboration Agreement, with Algeta ASA, referred to herein as Algeta, for the development of epratuzumab to be conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload. On August 2, 2013, an amendment to the Collaboration Agreement was entered into between the two companies modifying certain delivery and supply parameters. Under the terms of the Collaboration Agreement, as amended, the Company is required to manufacture and supply clinical-grade epratuzumab to Algeta, which has rights to evaluate the potential of a Targeted Thorium Conjugate (TTC), linking thorium-227 to epratuzumab, for the treatment of patients with cancer. Algeta will fund all non-clinical and clinical development costs up to the end of Phase 1 clinical testing. Upon successful completion of Phase 1 testing, the parties shall negotiate terms for a license agreement at Algeta’s request. The Company and Algeta agreed to certain parameters in the Collaboration Agreement. Under the terms of the Collaboration Agreement, as amended, Immunomedics received an upfront cash payment and other payments which have been recognized upon the Company fulfilling its obligations under the Collaboration Agreement. For the nine-month period ended March 31, 2014, the Company recognized $4.6 million of revenue under this arrangement, which was included in license fee and other revenues, while the related costs of $1.2 million was included in cost of license fee and other revenue. No such revenue was recognized for the three-month period ended March 31, 2014. For the three and nine-month periods ended March 31, 2015, the Company has recognized revenue of $0.3 million under this arrangement. The Bayer Group, referred to herein as Bayer, has acquired all of the shares and voting rights in Algeta ASA and the program with Immunomedics has been formally transferred to Bayer (Algeta).

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11	Commitments and Contingencies
	Employment Contracts
	Effective July 1, 2011, the Company entered into the Third Amended and Restated Employment Agreement with Dr. Goldenberg for his service to the Company as the Chief Scientific Officer (the “Goldenberg Agreement”), which terminates July 1, 2016. This agreement covers aspects of his compensation as well as duties and responsibilities at Immunomedics. Under this agreement Dr. Goldenberg’s annual base salary is at a minimum of $0.5 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased 3.5% to $0.6 million for the 2015 fiscal year). Dr. Goldenberg will also be eligible to participate in any Company incentive compensation plan in place for its senior level executives and is eligible to receive an annual discretionary bonus based upon certain performance standards to be determined by the Compensation Committee. Dr. Goldenberg’s annual bonus target is 50% of his annual base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount.
	Under the Goldenberg Agreement, Dr. Goldenberg is eligible to receive certain additional incentive compensation during the agreement term, including being eligible to receive royalty payments from royalties received by the Company. For each fiscal year, the Company shall pay Dr. Goldenberg a sum equal to a percentage of the annual royalties the Company receives on each of the products for which Dr. Goldenberg is an inventor, and all products using, related to or derived from products for which Dr. Goldenberg is an inventor. The percentage of royalties that the Company will pay to Dr. Goldenberg on each patented product will be determined based on the percentage of royalties that the Company receives from external third parties.
	Under the terms of the Goldenberg Agreement, the Company makes a minimum quarterly payment of $37.5 thousand to Dr. Goldenberg during each of the fiscal years during the Goldenberg Agreement, as an advance against the amounts due as additional incentive compensation, royalty payments and dispositions of undeveloped assets. For the three and nine-month periods ended March 31, 2015 and 2014, no additional incentive payments were made to Dr. Goldenberg.
	On July 1, 2014, the Company and Cynthia L. Sullivan entered into the Fifth Amended and Restated Employment Agreement pertaining to Ms. Sullivan’s service as the Company’s President and Chief Executive Officer. The Amended Sullivan Agreement shall terminate on July 1, 2017. Ms. Sullivan’s annual base salary under the agreement is $0.6 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee (increased by 3.5% for the 2015 fiscal year). Ms. Sullivan is also eligible to participate in the Company’s incentive compensation plan in place for its senior level executives. Ms. Sullivan’s annual bonus target is 50% of her base salary, subject to achievement of performance goals, with a potential payout from 0 to 150% of the target amount. Ms. Sullivan will also be eligible to receive equity compensation awards under the Company’s 2014 Long-Term Incentive Plan, or any such successor equity compensation plan as may be in place from time to time.
	Legal Matters
	The following is a summary of legal matters that are outstanding:
	Shareholder complaints:
	Two separate shareholder derivative complaints have been filed against the Company. First, on March 24, 2014, a complaint styled Kops v. Goldenberg, et al., was filed in the Superior Court of New Jersey, Chancery Division, General Equity Part, Morris County. Second, on April 18, 2014, a complaint styled Breitman v. Sullivan, et al., was filed in the United States District Court for the District of New Jersey. The complaints allege, among other things, that the Company and certain directors and officers breached their fiduciary duties for disseminating false and misleading information relating to the termination of the Nycomed Agreement. In particular, the complaints allege that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaints allege that the breaches in fiduciary duties by the directors and officers caused damages to the Company and stockholders, including a decline in value of the Company’s common stock, increased investigatory and litigation costs, and exposure to civil liability as a result of a pending securities fraud class action suit. Plaintiffs bring the derivative actions to recover damages against the directors and officers for the benefit of the Company, and to require the Company to reform and improve its corporate governance and internal procedures. On February 13, 2015, the Kops matter was dismissed without prejudice pursuant to a stipulation entered into by the parties. The Breitman matter is presently stayed pending the outcome of a motion to dismiss in a related putative class action lawsuit, described below. The defendants believe that the allegations in the derivative complaints are without merit and intend to defend the lawsuits vigorously; however, there can be no assurance regarding the ultimate outcome of these lawsuits.
	A putative class action lawsuit, styled Nasyrova v. Immunomedics, Inc., was filed on February 27, 2014, in the United States District Court for the District of New Jersey. The lawsuit alleges that the Company and certain of its current and former officers and directors failed to disclose and/or made material misstatements in the Company’s public filings relating to the termination of the Nycomed Agreement. In particular, the complaint alleges that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On June 24, 2014 the District Court entered an order appointing John Neff as lead plaintiff and The Rosen Law Firm, P.A. as lead counsel. Lead plaintiff and lead counsel thereafter filed an Amended Class Action Complaint on August 8, 2014. The defendants believe that the allegations in the class action complaint are without merit and intend to defend the lawsuit vigorously. Defendants moved to dismiss the complaint on September 22, 2014. On January 29, 2015 the United States District Court for the District of New Jersey granted the Company’s motion to dismiss the complaint in its entirety. The Court’s opinion concluded that Immunomedics had no duty to disclose issues raised with Takeda-Nycomed prior to the termination of the Nycomed Agreement. The Court granted Plaintiffs thirty days from the date of the opinion in order to file an amended complaint. On February 27, 2015 a second amended complaint was filed by the plaintiff alleging failure to disclose information related to the status of the agreement. The Company filed a motion to dismiss the second amended complaint on April 13, 2015. The defendants continue to believe that the allegations in the class action complaint are without merit and intend to defend the lawsuit vigorously.
	Immunomedics is also a party to various claims and litigation arising in the normal course of business, which includes some or all of certain of its patents. While it is not possible to determine the outcome of these matters, the Company believes that the resolution of all such matters will not have a material adverse effect on its consolidated financial position or liquidity, but could possibly be material to its consolidated results of operations in any one accounting period.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation and Presentation	Principles of Consolidation and Presentation
	The condensed consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the condensed consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Financial Instruments	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Marketable Securities	Marketable Securities
	Marketable securities, all of which are available-for-sale, consists of corporate debt securities, U.S. bonds and U.S. sponsored agencies and municipal bonds. Corporate debt securities include Eurodollar issues of U.S. corporations, and U.S. dollar denominated issues of foreign corporations. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive (loss) income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).
Inventory	Inventory
	Inventory, which consists only of the finished product of LeukoScan®, is stated at the lower of cost (which approximates first-in, first-out) or market, and includes materials, labor and manufacturing overhead.
Revenue Recognition	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition,” at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
Research and Development Costs	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with their clinical sites.
Reimbursement of Research & Development Costs	Reimbursement of Research & Development Costs
	Research and development costs that are reimbursable under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
Stock-Based Compensation	Stock-Based Compensation
	At the Annual Stockholder Meeting on December 3, 2014, the Company’s stockholders approved the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan replaced the Company’s 2006 Stock Incentive Plan (the “2006 Plan”), which terminated on December 3, 2014. The approval authorized the sum of 9,000,000 shares plus the number of unallocated shares available for issuance as of the effective date under the 2006 Plan that were not subject to outstanding awards.
	The Plan enables the grant of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards. The Plan is described more fully in Note 7 to these condensed consolidated financial statements.
	The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes-Merton option pricing formula for determining the grant-date fair value of such awards.
	The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk free interest rate is based upon the implied yields currently available from the U.S. Treasury yield curve in effect at the time of the grant. Pre-vesting forfeiture rates are estimated based upon past voluntary termination behavior and past option forfeitures.
	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the nine-month periods ended March 31, 2015 and 2014:
		Nine-Month Period Ended March 31,
		2015	2014
	Expected dividend yield	0%	0%
	Expected option term (years)	5.07	3.47
	Expected stock price volatility	59%	66%
	Risk-free interest rate	1.60%-1.67%	0.03%-1.79%
	Changes in any of these assumptions could impact, potentially materially, the amount of expense recorded in future periods related to stock-based awards.
Income Taxes	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of March 31, 2015.
	At June 30, 2014, the Company has available net operating loss carry forwards for federal income tax reporting purposes of approximately $173.4 million and for state income tax reporting purposes of approximately $66.2 million, which expire at various dates between fiscal 2015 and 2034. Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, the annual utilization of a company’s net operating loss and research credit carry forwards may be limited if the Company experiences a change in ownership of more than 50 percentage points within a three-year period.
	The majority-owned subsidiary of the Company (IBC Pharmaceuticals, Inc.) is currently under examination by the Internal Revenue Service for the fiscal year ended December 31, 2013.
	Income taxes were provided for profitable foreign jurisdictions at the estimated annual tax rate during the three and nine-month periods ended March 31, 2015 and 2014. The Company’s U.S. operations reported a net loss for the three and nine-month periods ended March 31, 2015 and 2014, resulting in a tax benefit that was fully offset by a valuation allowance.
	The Company has no liability for uncertain tax positions as of March 31, 2015.
Net Loss Per Share Allocable to Common Stockholders	Net Loss Per Share Allocable to Common Stockholders
	Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or conversion of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the three and nine-month periods ended March 31, 2015 and 2014. The common stock equivalents excluded from the diluted per share calculation are 26,759,915 and 7,388,212 shares at March 31, 2015 and 2014, respectively.
Net Comprehensive Loss	Net Comprehensive Loss
	Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the condensed consolidated statements of comprehensive loss.
Reclassification	Reclassification
	Certain prior period balances have been reclassified to conform to the current period presentation.
Accounting Pronouncements	Accounting Pronouncements
	In April 2015, the FASB issued Accounting Standard Update (“ASU”) 2015-03, “Interest – Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. Under the new ASU, debt issuance costs will be reported in the balance sheet as a direct deduction from the related debt liability rather than as a separate asset. Amortization of the costs is reported as interest expense. The amendments in this update are effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted for financial statements that have not been previously issued. The Company has adopted this standard in the current interim period and have presented the debt issuance costs related to the Convertible Notes as a direct deduction from the related face value in the accompanying condensed consolidated balance sheet.
	In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements – Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This guidance clarifies that an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The amendments in this update are effective for annual reporting periods ending after December 15, 2016, and annual and interim periods thereafter, and early application is permitted. The Company is assessing ASU 2014-15’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-12’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. On April 1, 2015, the FASB voted to propose to defer the effective date on the new revenue recognition standard by one year. Therefore, public organizations would apply the new standard to annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Options Weighted-Average Assumptions	The following table sets forth the weighted-average assumptions used to calculate the fair value of options granted for the nine-month periods ended March 31, 2015 and 2014:
		Nine-Month Period Ended March 31,
		2015	2014
	Expected dividend yield	0%	0%
	Expected option term (years)	5.07	3.47
	Expected stock price volatility	59%	66%
	Risk-free interest rate	1.60%-1.67%	0.03%-1.79%

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Components of Marketable Securities	Marketable securities at March 31, 2015 consist of the following (in thousands):
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		(Loss)
	March 31, 2015
	U.S. Treasury Bonds	$	13,690	$	12	$	—		$	13,702
	U.S. Government Sponsored Agencies		46,383		21		(9	)		46,395
	Corporate Debt Securities		30,051		5		(24	)		30,032
		$	90,124	$	38	$	(33	)	$	90,129
	Marketable securities at June 30, 2014 consist of the following (in thousands):
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds	$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies		7,458		—		(1	)		7,457
	Corporate Debt Securities		18,876		12		(11	)		18,877
		$	34,871	$	13	$	(13	)	$	34,871
Maturities of Debt Securities Classified as Available-for-Sale	Maturities of debt securities classified as available-for-sale were as follows at March 31, 2015 (in thousands):
		Fair Value		Net Carrying
				Amount
	Due within one year	$	38,344	$	38,442
	Due after one year through five years		51,785		52,064
		$	90,129	$	90,506
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
		Fair Value		Net Carrying
				Amount
	Due within one year	$	25,336	$	25,449
	Due after one year through five years		9,535		9,603
		$	34,871	$	35,052

Estimated_Fair_Value_of_Financ1

Estimated Fair Value of Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Financial Assets Recorded on Condensed Consolidated Balance Sheets	Financial assets recorded on the condensed consolidated balance sheets as of March 31, 2015 and June 30, 2014 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			($ in thousands)
	March 31, 2015		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	11,859	$	—	$	—	$	11,859
	Marketable Securities:
	U.S. Treasury Bonds			13,702		—		—		13,702
	U.S. Government Sponsored Agencies			46,395		—		—		46,395
	Corporate Debt Securities			30,032		—		—		30,032
	Total		$	101,988	$	—	$	—	$	101,988
			($ in thousands)
	June 30, 2014		Level 1		Level 2		Level 3		Total
	Money Market Funds		$	367	$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537		—		—		8,537
	U.S. Government Sponsored Agencies			7,457		—		—		7,457
	Corporate Debt Securities			18,877		—		—		18,877
	Total		$	35,238	$	—	$	—	$	35,238

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized			Accumulated Other
			Translation			(Losses) Gains  on			Comprehensive
			Adjustments			Available-for-Sale			Income
						Securities
	Balance, July 1, 2014		$	261,924		$	(87	)	$	261,837
	Other comprehensive (loss) income before reclassifications			(511,335	)		15,972			(495,363	)
	Amounts reclassified from accumulated other comprehensive income (loss)(a)			—			(10,203	)		(10,203	)
	Net current-period other comprehensive (loss) income			(511,335	)		5,769			(505,566	)
	Balance, March 31, 2015		$	(249,411	)	$	5,682		$	(243,729	)
	Balance, July 1, 2013		$	161,830		$	—		$	161,830
	Other comprehensive income before reclassifications			123,236			15,077			138,313
	Amounts reclassified from accumulated other comprehensive income(a)			—			(4,193	)		(4,193	)
	Net current-period other comprehensive income			123,236			10,884			134,120
	Balance, March 31, 2014		$	285,066		$	10,884		$	295,950
	(a)	For the nine-months ended March 31, 2015 and 2014, $10,203 and $4,193 was reclassified from accumulated other comprehensive income to interest and other income, respectively.

Stock_Incentive_Plan_Tables

Stock Incentive Plan (Tables)	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Options	Information concerning options for the nine-month period ended March 31, 2015 is summarized as follows:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding, July 1, 2014		5,308,617		$	3.41
	Granted		694,923		$	3.57
	Exercised		(178,625	)	$	3.03
	Cancelled or forfeited		(399,750	)	$	4.54
	Outstanding, March 31, 2015		5,425,165		$	3.34		3.24	$	3,817,459
	Exercisable, March 31, 2015		4,105,123		$	3.18		2.42	$	3,441,461
Non-Vested Restricted and Performance Stock Units	A summary of the Company’s non-vested restricted and performance stock units at July 1, 2014, and changes during the nine-month period ended March 31, 2015 are presented below:
	Outstanding Non-Vested	Number
	Restricted and Performance Stock Units	of Awards
	Non-vested at July 1, 2014		788,364
	Restricted Units Granted		277,313
	Vested		—
	Exercised		(314,287	)
	Non-vested at March 31, 2015		751,390

Geographic_Segments_Tables

Geographic Segments (Tables)	9 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Financial Information Based on Geographic Location of Facilities	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three and nine-months ended March 31, 2015 and 2014 ($ in thousands):
		As of and for the
		three-months ended
		March 31, 2015
		United			Europe			Total
		States
	Total assets	$	110,600		$	1,234		$	111,834
	Property and equipment, net		2,056			9			2,065
	Revenues		489			694			1,183
	(Loss) before taxes		(11,762	)		(23	)		(11,785	)
		As of and for the
		three-months ended
		March 31, 2014
		United			Europe			Total
		States
	Total assets	$	24,074		$	2,179		$	26,253
	Property and equipment, net		1,980			—			1,980
	Revenues		242			912			1,154
	(Loss) income before taxes		(9,586	)		53			(9,533	)
		Nine-months ended
		March 31, 2015
		United			Europe			Total
		States
	Revenues	$	1,110		$	2,147		$	3,257
	(Loss) income before taxes		(35,733	)		79			(35,654	)
		Nine-months ended
		March 31, 2014
		United			Europe			Total
		States
	Revenues	$	5,453		$	2,402		$	7,855
	(Loss) before taxes		(23,588	)		(68	)		(23,656	)

Business_Overview_and_Basis_of1

Business Overview and Basis of Presentation - Additional Information (Detail) (USD $)	9 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2015
	Subsidiary
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of subsidiaries	2
Cash, cash equivalents and marketable securities	$106,200,000
Utilized cash aggregated	-30,379,543	-21,441,445
4.75% Convertible Senior Notes Due 2020 [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Debt instrument, face amount			100,000,000
Debt instrument, stated percentage			4.75%
Debt instrument, maturity year	2020
Net proceeds from debt			$96,300,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Significant Accounting Policies [Line Items]
Highly liquid investments, original maturity period	3 months
Common stock reserved for possible future issuance upon exercise of stock options	18,434,788
Operating loss carry forwards for federal income tax			$173,400,000
Operating loss carry forwards for state income tax			66,200,000
Time period over percentage change of ownership occur	3 years
Liability for uncertain tax positions	$0
Common stock equivalents excluded from the diluted per share calculation	26,759,915	7,388,212
Minimum [Member]
Significant Accounting Policies [Line Items]
Net operating loss carry forwards expiration year	2015
Expected change in ownership percentage	50.00%
Maximum [Member]
Significant Accounting Policies [Line Items]
Net operating loss carry forwards expiration year	2034
2006 Stock Incentive Plan [Member]
Significant Accounting Policies [Line Items]
Common stock reserved for possible future issuance upon exercise of stock options	9,000,000
Long term incentive plan, termination date	3-Dec-14

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Options Weighted-Average Assumptions (Detail)	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected dividend yield	0.00%	0.00%
Expected option term (years)	5 years 26 days	3 years 5 months 19 days
Expected stock price volatility	59.00%	66.00%
Risk-free interest rate, minimum	1.60%	0.03%
Risk-free interest rate, maximum	1.67%	1.79%

Marketable_Securities_Componen

Marketable Securities - Components of Marketable Securities (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$90,124	$34,871
Gross Unrealized Gain	38	13
Gross Unrealized (Loss)	-33	-13
Fair Value	90,129	34,871
U.S. Treasury Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	13,690	8,537
Gross Unrealized Gain	12	1
Gross Unrealized (Loss)		-1
Fair Value	13,702	8,537
US Government Agencies Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	46,383	7,458
Gross Unrealized Gain	21
Gross Unrealized (Loss)	-9	-1
Fair Value	46,395	7,457
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	30,051	18,876
Gross Unrealized Gain	5	12
Gross Unrealized (Loss)	-24	-11
Fair Value	$30,032	$18,877

Marketable_Securities_Maturiti

Marketable Securities - Maturities of Debt Securities Classified as Available-for-Sale (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Investments, Debt and Equity Securities [Abstract]
Fair Value, Due within one year	$38,344	$25,336
Fair Value, Due after one year through five years	51,785	9,535
Fair Value	90,129	34,871
Net Carrying Amount, Due within one year	38,442	25,449
Net Carrying Amount, Due after one year through five years	52,064	9,603
Net Carrying Amount	$90,506	$35,052

Convertible_Senior_Notes_Addit

Convertible Senior Notes - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
	Feb. 28, 2015	Mar. 31, 2015	Mar. 31, 2015
Debt Instrument [Line Items]
Amortization of debt issuance costs			$99,337
4.75% Convertible Senior Notes Due 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	100,000,000
Issuance of 4.75% convertible senior notes - net	96,300,000
Debt issuance costs	3,700,000
Debt instrument, maturity date			15-Feb-20
Frequency of interest payments			Interest at 4.75% will be payable semiannually on February 15 and August 15 of each year, beginning on August 15, 2015.
Debt instrument, stated percentage	4.75%
Debt instrument, effective interest rate		5.48%	5.48%
Number of shares issuable under conversion of debt	19,600,000
Debt conversion ratio	0.1958336
Conversion price of debt	$5.11
Convertible Notes, terms of conversion			The conversion rate will initially be 195.8336 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $5.11 per share of Immunomedics common stock)
Percentage of principal amount redeemable	100.00%
Interest expense		700,000	700,000
Amortization of debt issuance costs		$100,000	$100,000

Estimated_Fair_Value_of_Financ2

Estimated Fair Value of Financial Instruments - Financial Assets Recorded on Condensed Consolidated Balance Sheets (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$101,988	$35,238
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	11,859	367
U.S. Treasury Bonds [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	13,702	8,537
U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	46,395	7,457
Corporate Debt Securities [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	30,032	18,877
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	101,988	35,238
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	11,859	367
Level 1 [Member] | U.S. Treasury Bonds [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	13,702	8,537
Level 1 [Member] | U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	46,395	7,457
Level 1 [Member] | Corporate Debt Securities [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$30,032	$18,877

Estimated_Fair_Value_of_Financ3

Estimated Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Mar. 31, 2015
In Millions, unless otherwise specified
Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]
Estimated fair value of Convertible Notes	$99.60

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 03, 2014	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total shares authorized		165,000,000
Common stock, shares authorized	155,000,000	155,000,000	135,000,000
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Shelf registration process, securities total dollar amount	$130
Shelf registration process, description	Company may issue, in one or more offerings, any combination of common stock, preferred stock senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $130.0 million.
Previously Reported [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total shares authorized		145,000,000
Common stock, shares authorized		135,000,000
Preferred stock, shares authorized		10,000,000

Stockholders_Equity_Components

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning, Balance			$261,837	$161,830
Other comprehensive (loss) income before reclassifications			-495,363	138,313
Amounts reclassified from accumulated other comprehensive income			-10,203	-4,193
Other comprehensive (loss) income	-237,282	-783	-505,566	134,120
Ending, Balance	-243,729	295,950	-243,729	295,950
Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning, Balance			261,924	161,830
Other comprehensive (loss) income before reclassifications			-511,335	123,236
Other comprehensive (loss) income			-511,335	123,236
Ending, Balance	-249,411	285,066	-249,411	285,066
Net Unrealized (Losses) Gains on Available-for-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning, Balance			-87
Other comprehensive (loss) income before reclassifications			15,972	15,077
Amounts reclassified from accumulated other comprehensive income			-10,203	-4,193
Other comprehensive (loss) income			5,769	10,884
Ending, Balance	$5,682	$10,884	$5,682	$10,884

Stockholders_Equity_Components1

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassified from accumulated other comprehensive income	$32,838	$15,179	$69,126	$39,695
Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassified from accumulated other comprehensive income			$10,203	$4,193

Stock_Incentive_Plan_Additiona

Stock Incentive Plan - Additional Information (Detail) (USD $)	9 Months Ended		3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Aug. 14, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for possible future issuance upon exercise of stock options	18,434,788		18,434,788		18,434,788
Stock vesting period	4 years
Contractual terms of stock option	7 year
Stock options available for future grants	6,176,555		6,176,555		6,176,555
Performance Units available for grant	12,258,233		12,258,233		12,258,233
Weighted average fair value at the date of grant for options granted	$1.61	$1.94
Expected option term (years)	5 years 26 days	3 years 5 months 19 days
Non-vested options outstanding	2,071,432		2,071,432		2,071,432
Unrecognized compensation costs related to non-vested share-based compensation	$3,100,000
Weighted-average period recognized	2 years 7 months 6 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period	4 years
Value of shares to be granted for non-employee Board members	45,000
Stock-based compensation expense	135,000	159,000	44,000	44,000
Performance Units, vested	0
Remaining performance units, Granted	277,313
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares to be granted for non-employee Board members	45,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Units available for grant	389,864		389,864		389,864
Unrecognized compensation costs related to non-vested share-based compensation	500,000
Weighted-average period recognized	2 years 2 months 12 days
Performance Units, vested					116,959
Remaining performance units, Granted					272,905
Stock-based compensation	300,000	1,300,000	100,000	500,000
Performance Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period	5 years
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for possible future issuance upon exercise of stock options	9,000,000		9,000,000		9,000,000
Long term incentive plan, termination date	3-Dec-14
Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual terms of stock option	7 year
Employees, Executive Officers and Non-Employee Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related stock options	2,100,000	2,400,000	600,000	900,000
Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to non-vested share-based compensation	1,400,000
Weighted-average period recognized	2 years 6 months
Restricted stock units						226,657
Restricted stock units, market price						$3.32
Executive Officers [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related stock options	$600,000	$500,000	$200,000	$200,000

Stock_Incentive_Plan_Summary_o

Stock Incentive Plan - Summary of Options (Detail) (USD $)	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Options outstanding, beginning of year	5,308,617
Number of Shares, Options granted	694,923
Number of shares, Options Exercised	-178,625
Number of Shares, Options cancelled or forfeited	-399,750
Number of Shares, Options outstanding, end of year	5,425,165
Number of Shares, Options exercisable, end of year	4,105,123
Weighted Average Exercise Price, Options outstanding, beginning of year	$3.41
Weighted Average Exercise Price, Options granted	$3.57
Weighted Average Exercise Price, Options granted,Exercised	$3.03
Weighted Average Exercise Price, Options cancelled or forfeited	$4.54
Weighted Average Exercise Price, Options outstanding, end of year	$3.34
Weighted Average Exercise Price, Options exercisable, end of year	$3.18
Weighted Average Remaining Contractual Life of outstanding stock options	3 years 2 months 27 days
Weighted Average Remaining Contractual Life of exercisable stock options	2 years 5 months 1 day
Aggregate Intrinsic Value of outstanding stock options	$3,817,459
Aggregate Intrinsic Value of exercisable stock options	$3,441,461

Stock_Incentive_Plan_NonVested

Stock Incentive Plan - Non-Vested Restricted and Performance Stock Units (Detail) (Restricted Stock [Member])	9 Months Ended
	Mar. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at July 1, 2014	788,364
Granted	277,313
Vested	0
Exercised	-314,287
Non-vested at March 31, 2015	751,390

Geographic_Segments_Financial_

Geographic Segments - Financial Information Based on Geographic Location of Facilities (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Segment Reporting Information [Line Items]
Total assets	$111,833,625	$26,253,000	$111,833,625	$26,253,000	$47,486,482
Property and equipment, net	2,065,311	1,980,000	2,065,311	1,980,000	1,895,475
Revenues	1,182,698	1,154,341	3,257,487	7,854,612
(Loss) income before taxes	-11,784,823	-9,532,589	-35,654,380	-23,656,451
United States [Member]
Segment Reporting Information [Line Items]
Total assets	110,600,000	24,074,000	110,600,000	24,074,000
Property and equipment, net	2,056,000	1,980,000	2,056,000	1,980,000
Revenues	489,000	242,000	1,110,000	5,453,000
(Loss) income before taxes	-11,762,000	-9,586,000	-35,733,000	-23,588,000
Europe [Member]
Segment Reporting Information [Line Items]
Total assets	1,234,000	2,179,000	1,234,000	2,179,000
Property and equipment, net	9,000		9,000
Revenues	694,000	912,000	2,147,000	2,402,000
(Loss) income before taxes	($23,000)	$53,000	$79,000	($68,000)

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Research related activities charges	$10,385,422	$8,141,744	$30,142,289	$23,221,651
Compensation received for services	21,000	20,000	63,000	59,000
Center for Molecular Medicine and Immunology [Member]
Related Party Transaction [Line Items]
Legal expenses incurred by the company	8,000	10,000	30,000	23,000
Research related activities charges	$0	$0	$0	$0

License_and_Collaboration_Agre1

License and Collaboration Agreements - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	9 Months Ended		0 Months Ended	3 Months Ended
	Dec. 27, 2011	Jan. 31, 2012	Mar. 31, 2014	Mar. 31, 2015	9-May-06	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Guarantor Obligations [Line Items]
Non-refundable cash payment received		$30,000,000
Duration of warrant issued	5 years
Number of shares under five year warrant	1,000,000
Shares to be purchased under warrant, par value	$0.01			0.01		$0.01		$0.01
Shares to be purchased under warrant, exercise price	$8
Cost of license fee and other revenues			1,189,170
Nycomed Agreement [Member]
Guarantor Obligations [Line Items]
License agreement date				11-Jul-08
Acquisition completion date				30-Sep-11
UCB Agreement [Member]
Guarantor Obligations [Line Items]
License agreement date				9-May-06
Non-refundable cash payment received					38,000,000
Amendment agreement date				27-Dec-11
Product royalties term, description				The Company is also entitled to product royalties ranging from a mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement and Amendment Agreement during the product royalty term, (subject to reduction in certain circumstances).
Termination period				60 days
Additional amounts payable after effective date of termination				0
UCB Agreement [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Cash payment receivable				145,000,000
Equity investments receivable				20,000,000
Achievement of specified product sales milestones				260,000,000
The Bayer Group [Member]
Guarantor Obligations [Line Items]
Collaboration agreement date				2013-01
Collaboration agreement amendment date				2-Aug-13
License fee revenue			4,600,000	300,000		300,000	0
Cost of license fee and other revenues			$1,200,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2015
	Complaints
Guarantor Obligations [Line Items]
Number of shareholder derivative complaints	2
Goldenberg Agreement [Member]
Guarantor Obligations [Line Items]
Minimum additional incentive compensation, royalty payments and disposition of undeveloped assets	37,500
Additional incentive compensation paid	0	0	0	0
Nycomed Agreement [Member]
Guarantor Obligations [Line Items]
Agreement termination date	9-Oct-13
Employment Agreement [Member] | Goldenberg Agreement [Member]
Guarantor Obligations [Line Items]
Annual base salary					500,000
Percentage of increase in annual base salary in current fiscal year	3.50%
Percentage of annual bonus target	50.00%
Agreement termination date	1-Jul-16
Agreement date	1-Jul-11
Employment Agreement [Member] | Goldenberg Agreement [Member] | Scenario Forecast [Member]
Guarantor Obligations [Line Items]
Annual base salary						600,000
Employment Agreement [Member] | Goldenberg Agreement [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Percentage of potential payout target	0.00%
Employment Agreement [Member] | Goldenberg Agreement [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Percentage of potential payout target	150.00%
Employment Agreement [Member] | Sullivan Agreement [Member]
Guarantor Obligations [Line Items]
Annual base salary	600,000
Percentage of increase in annual base salary in current fiscal year	3.50%
Percentage of annual bonus target	50.00%
Agreement termination date	1-Jul-17
Agreement date	1-Jul-14
Employment Agreement [Member] | Sullivan Agreement [Member] | Minimum [Member]
Guarantor Obligations [Line Items]
Percentage of potential payout target	0.00%
Employment Agreement [Member] | Sullivan Agreement [Member] | Maximum [Member]
Guarantor Obligations [Line Items]
Percentage of potential payout target	150.00%
First Lawsuit [Member]
Guarantor Obligations [Line Items]
Lawsuit filing date	24-Mar-14
Second Lawsuit [Member]
Guarantor Obligations [Line Items]
Lawsuit filing date	18-Apr-14
Class Action Lawsuits [Member]
Guarantor Obligations [Line Items]
Lawsuit filing date	27-Feb-14